101. Vascular endothelial growth factor, tissue factor, coagulation and fibrinolysis markers in slow-flow vascular malformations: a prospective study of treatment with sirolimus.
- Author
-
Maruani, Annabel, Moineau, Anne-Guillemette, Boccara, Olivia, Mazereeuw-Hautier, Juliette, Leducq, Sophie, Bessis, Didier, Guibaud, Laurent, Vabres, Pierre, Mallet, Stephanie, Barbarot, Sebastien, Chiaverini, Christine, Droitcourt, Catherine, Bursztejn, Anne-Claire, Lengelle, Céline, Woillard, Jean-Baptiste, Herbreteau, Denis, Touze, Anne Le, Binet, Aurélien, Morel, Baptiste, and Bourgoin, Hélène
- Subjects
FIBRIN fragment D ,VASCULAR endothelial growth factors ,RAPAMYCIN ,FIBRINOLYSIS ,BLOOD coagulation ,HUMAN abnormalities - Abstract
Https://doi.org/10.1093/bjd/ljac028 Dear Editor, Slow-flow vascular malformations (VMs), particularly venous VMs, might get complicated by intramalformative thrombosis linked to localized intravascular coagulopathy (LIC).[[1], [3]] Several studies have shown the effectiveness of sirolimus on slow-flow VMs but its effect on coagulation has been poorly studied.[3] Moreover, vascular endothelial growth factor (VEGF) A and C are known for their proangiogenic and lymphangiogenic activities, respectively, and sirolimus may reduce their levels.[4] In this study, we investigated blood levels of VEGF-A and -C, tissue factor (TF) and coagulation markers in children with slow-flow VMs before and after sirolimus treatment. Overall, 82% of patients with venous VMs ( I n i = 18) and 63% with combined VMs ( I n i = 12) had increased D-dimer; two had low fibrinogen. Two studies involving 24 and 62 children with venous VMs reported elevated D-dimer in 33% and 39% of patients, respectively.[2],[7] The proportion of patients with increased D-dimer in venous VMs was higher in our study (82%). [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF